Vaz FragosoCA, GillTM, McAvayG, Van NessPH, YaggiHK, ConcatoJ. Use of lambda-mu-sigma-derived z score for evaluating respiratory impairment in middle-aged persons. Respir Care, 2011; 56(11):1771–1777.
2.
AggarwalAN, GuptaD, AgarwalR, JindalSK. Comparison of the lower confidence limit to the fixed-percentage method for assessing airway obstruction in routine clinical practice. Respir Care, 2011; 56(11):1778–1784.
American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis, 1991; 144(5 part 1):1202–1218.
5.
QuanjerPH, TammelingGJ, CotesJE, PedersenOF, PeslinR, YernaultJ-C. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal, Official Statement of the European Respiratory Society. Eur Respir J, 1993; 6(Suppl 16):5–40.
LevyML, QuanjerPH, BookerR, CooperBG, HolmesS, SmallI. Diagnostic spirometry in primary care: proposed standards for general practice compliant with American Thoracic Society and European Respiratory Society recommendations: a General Practice Airways Group (GPIAG) document, in association with the Association for Respiratory Technology & Physiology (ARTP) and Education for Health. Prim Care Respir J, 2009; 18(3):130–147.
8.
BatesDV, ChristieRV. Respiratory function in disease. Philadelphia: Saunders; 1964:91.
9.
SobolBJ. Assessment of ventilatory abnormality in the asymptomatic subject: an exercise in futility. Thorax, 1966; 21(5):445–449.
10.
MillerMR, PincockAC. Predicted values: how should we use them?. (editorial) Thorax, 1988; 43(4):265–267.
11.
SobolBJ, SobolPG. Per cent of predicted as the limit of normal in pulmonary function testing: a statistically valid approach (editorial). Thorax, 1979; 34(1):1–3.
12.
HardieJA, BuistAS, VollmerWM, EllingsenI, BakkePS, MørkveO. Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J, 2002; 20(5):1117–1122.
13.
CerveriI, CorsicoAG, AccordiniS, NinianoR, AnsaldoE, AntóJM, et al. Underestimation of airflow obstruction among young adults using FEV1/FVC < 70% as a fixed cut-off; a longitudinal evaluation of clinical and functional outcomes. Thorax, 2008; 63(12):1040–1045.
14.
HoeseinFAAM, ZanenP, LammersJ-WJ. Lower limit of normal or FEV1/FVC <0.70 in diagnosing COPD: an evidence-based review. Respir Med, 2011; 105(6):907–915.
15.
ManninoDM, BuistAS, VollmerWM. Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function?. Thorax, 2007; 62(3):237–241.
16.
ManninoDM, BuistAS, VollmerWM. Authors' reply to two letters to the editor. Thorax, 2007; 62(12):1108–1109.
17.
Garcia-AymerichJ, PonsIS, ManninoDM, MaasAK, MillerDP, DavisKJ. Lung function impairment, COPD hospitalisations and subsequent mortality. Thorax, 2011; 66(7):85–590.
18.
ManninoDM. Understanding COPD hospitalizations: the devil is always in the details!. Chest, 2007; 132(60):1731–1732.
19.
DamarlaM, CelliBR, MullerovaHX, Pinto-PlataVM. Discrepancy in the use of confirmatory tests in patients hospitalized with the diagnosis of chronic obstructive pulmonary disease or congestive heart failure. Respir Care, 2006; 51(10):1120–1124.
20.
Ekberg-AronssonM, PehrssonK, NilssonJÅ, NilssonPM, LöfdahlCG. Mortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitis. Respir Res, 2005; 6(1):98.
21.
Vaz FragosoCA, ConcatoJ, McAvayG, Van NessPH, RochesterCL, Klar YaggiH, GillTM. Chronic obstructive pulmonary disease in older persons: a comparison of two spirometric definitions. Respir Med, 2010; 104(8):1189–1196.
22.
MillerMR, PedersenOF, DirksenA. A new staging strategy for chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis, 2007; 2(4):657–663.
23.
BridevauxPO, GerbaseMW, Probst-HenschNM, SchindlerC, GaspozJM, RochatT. Long-term decline in lung function, utilisation of care and quality of life in modified GOLD stage 1 COPD. Thorax, 2008; 63(9):768–774.
24.
MillerMR, QuanjerPH, SwanneyMP, RuppelG, EnrightPL. Interpreting lung function data using 80% predicted and fixed thresholds misclassifies more than 20% of patients. Chest, 2011; 139(1):52–59.
25.
Vaz FragosoCA, ConcatoJ, McAvayG, Van NessPH, RochesterC, Klar YaggiH, GillTM. The ratio of forced expiratory volume in 1-second to forced vital capacity as a basis for establishing chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2010; 181(5):446–451.
26.
StanojevicS, WadeA, StocksJ, HankinsonJ, CoatesAL, PanH, et al. Reference ranges for spirometry across all ages. Am J Respir Crit Care Med, 2008; 177(3):253–260.
27.
StanojevicS, WadeA, StocksJ. Reference values for lung function: past, present and future. Eur Respir J, 2010; 36(1):12–19.
28.
QuanjerPH, EnrightPL, RuppelG. The GOLD guidelines definition of mild airway obstruction. Respir Care, 2010; 55(10):1397–1398.
29.
QuanjerPH, EnrightPL, MillerMR, StocksJ, RuppelG, SwanneyMR, et al. The need to change the method for defining mild airway obstruction. Eur Respir J, 2011; 37(3):720–722.
30.
VestboJ, Rodriguez-RoisinR. GOLD and the fixed ratio. Eur Respir J, 2011; 38(2):481–482.
31.
QuanjerPH, EnrightPL, RuppelG, MillerMR, Vaz FragosoCA, CooperBG, et al. GOLD and the fixed ratio. Eur Respir J, 2011; 38(2):482–483.
32.
QaseemA, WiltTJ, WeinbergerSE, HananiaNA, CrinerG, van der MolenT, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med, 2011; 155(3):179–191.
33.
SorliePD, KannelWB, O'ConnorG. Mortality associated with respiratory function and symptoms in advanced age. The Framingham Study. Am Rev Respir Dis, 1989; 140(2):379–384.
34.
HoleDJ, WattGCM, Davey-SmithG, HartCL, GillisCR, HawthorneVM. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ, 1996; 313(7059):711–715.
35.
KnuimanMW, JamesAL, DivitiniML, RyanG, BartholomewHC, MuskAW. Lung function, respiratory symptoms, and mortality: results from the Busselton health study. Ann Epidemiol, 1999; 9(5):297–306.
36.
SinDD, WuLL, Paul ManSFP. The relationship between reduced lung function and cardiovascular mortality. A population-based study and a systematic review of the literature. Chest, 2005; 127(6):1952–1959.
